PYA Covid-19 Information Hub
Modifier 25 and Same Day Services: How the Truth Finally Prevailed in a Recent Appeal
Published November 16, 2021

New Webinar: “Modifier 25 and Same Day Services: How the Truth Finally Prevailed in a Recent Appeal”

The Office of the Inspector General maintains Modifier 25 as a target of its work plan each year. One of the types of reviews under Modifier 25 audits is chemotherapy infusion on the same day as an evaluation and management (E/M) service. Recovery audit contractors (RACs), Medicare Administrative Contractors (MACs), Unified Program Integrity Contractors (UPICs), and commercial payers often perform these audits as well. The U.S. Department of Justice has also reached settlements with providers on this topic. Many providers have fought and lost the battle as their E/M is denied due to the lack of supporting documentation above and beyond the chemotherapy infusion.

PYA Principal Valerie Rock will join Myla Reizen, a partner with K&L Gates, to discuss an administrative law judge’s recent appeal decision in which a practice was successful in overcoming denials—a rare occurrence.

In this one-hour webinar, Valerie and Myla will cover the background and tactics of this successful appeal strategy, including:

  • The history of the bundling of an E/M in the chemotherapy infusion.
  • Understanding what the common clinical reasoning is for performing an E/M during the period of treatment cycles.
  • Advancing your strategies as we take a deep dive into examples of a successful appeal and tactics applied.

The webinar takes place at 11 a.m. Eastern, December 16, 2021.

Learn more and register

This webinar is part of PYA’s twice-monthly “Healthcare Regulatory Roundup” series in which experts from across the firm provide practical insights on the latest regulatory developments.

If you would like additional guidance related to billing with Modifier 25 or E/M, or for assistance with any matter related to compliance, valuation, or strategy and integration, contact a PYA executive below at (800) 270-9629.

 

Executive Contacts

Interested in Learning More?

Sign Up for Our Insights, Including COVID-19 Bulletins!



    Select Your Subscriptions